Inify Laboratories (INIFY) Q1 2026 earnings summary

Executive summary

• Sales increased by 17% year-over-year in Q1 2026, driven by growth in Swedish operations and initial UK market establishment.

• Laboratory operations in Sweden have delivered positive results for six consecutive quarters, with continued growth potential.

• UK laboratory installation completed; regulatory approval for clinical operations expected in Q2 2026.

• Extended accreditation to ISO 15189 for gastrointestinal diagnostics achieved after the reporting period.

Financial highlights

• Net sales reached SEK 6.0 million in Q1 2026, up from SEK 5.1 million in Q1 2025.

• EBITDA was SEK -18.1 million, compared to SEK -14.5 million in Q1 2025.

• Net result for the quarter was SEK -21.5 million, versus SEK -15.4 million in Q1 2025.

• Cash at period end was SEK 18.1 million, down from SEK 151.1 million a year earlier, reflecting investments in UK expansion.

• Equity ratio stood at 88.8% at quarter end.

Outlook and guidance

• Focus remains on growing Swedish business and penetrating the UK market.

• First patient samples from the UK expected in June 2026, slightly later than planned.

• Management sees significant growth potential in both prostate and gastrointestinal diagnostics.